Loading...
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Desp...
Na minha lista:
| Udgivet i: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889286/ https://ncbi.nlm.nih.gov/pubmed/31564718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0573-8 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|